BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, is currently developing immunotherapy solutions demonstrated to be highly effective and well tolerated by patients. The market share for immunotherapy treatments for breast cancer as well as other malignancies is forecasted to surge in the coming years. An article discussing the company reads, “Several studies indicate that the incidence of breast cancer is expected to increase in the next decade (http://ibn.fm/XR9CX). U.S. breast cancer diagnoses are anticipated to grow from 283,000 in 2011 to 441,000 in 2030, an increase of over 50 percent. The proportion of cases diagnosed among women in the 50–to–69 age group is expected to decrease from 55 percent to 44 percent in 2030. Diagnoses among those aged 70 to 84, however, will increase from 24 percent to 35 percent. . . . Immunotherapy could provide a viable solution to the problem. The cancer immunotherapy market is anticipated to grow to $145 billion by 2022, at a CAGR of 14 percent (http://ibn.fm/IBQyc). Immunotherapy currently accounts for 50 percent of the oncology medications market, but it is forecast that roughly 60 percent of previously treated cancer patients will adopt immunotherapy by 2026.”
To view the full article, visit http://ibn.fm/hywzI
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.